← Back to All US Stocks

Stimcell Energetics Inc. (STME) Stock Fundamental Analysis & AI Rating 2026

STME OTC Surgical & Medical Instruments & Apparatus NV CIK: 0001493712
Recently Updated • Analysis: Apr 16, 2026 • SEC Data: 2026-02-28
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 STME Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-268.6K
Current Ratio: 0.02x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence
Stimcell Energetics Inc. (STME) receives a STRONG SELL rating with 95% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $0, Stimcell Energetics Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete STME stock analysis for 2026.

Is Stimcell Energetics Inc. (STME) a Good Investment?

Claude

Stimcell Energetics is technically insolvent with negative stockholders equity of -$1.7M against only $34.5K in assets and zero revenue. The company is burning cash at -$268.6K annually with only $10.3K in reserves, creating acute bankruptcy risk within months absent emergency financing or asset acquisition.

Why Buy Stimcell Energetics Inc. Stock? STME Key Strengths

Claude
  • + Medical instruments sector could retain strategic value if company restructured or acquired
  • + Minimal debt burden relative to equity deficit
  • + Currently filing reports indicates ongoing corporate entity status

STME Stock Risks: Stimcell Energetics Inc. Investment Risks

Claude
  • ! Insolvency - liabilities ($1.7M) far exceed assets ($34.5K); negative equity of -$1.7M
  • ! Zero revenue and sustained operating losses of -$665.9K with no business generation
  • ! Acute liquidity crisis - current ratio 0.02x with only $10.3K cash against $1.7M liabilities; cash will deplete within weeks at current burn rate
  • ! Bankruptcy risk is imminent without emergency financing, merger, or significant operational turnaround
  • ! OTC trading with minimal transparency and insider activity absent

Key Metrics to Watch

Claude
  • * Cash position and monthly burn rate (survival timeline critical)
  • * Revenue generation restart (currently zero)
  • * Stockholders equity trajectory (currently -$1.7M)
  • * Any financing announcements, mergers, or asset acquisitions
  • * Debt covenant defaults or creditor actions

Stimcell Energetics Inc. (STME) Financial Metrics & Key Ratios

Revenue
$0.0
Net Income
$-665.9K
EPS (Diluted)
$0.00
Free Cash Flow
$-268.6K
Total Assets
$34.5K
Cash Position
$10.3K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

STME Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -1,929.0%
FCF Margin N/A

STME vs Healthcare Sector: How Stimcell Energetics Inc. Compares

How Stimcell Energetics Inc. compares to Healthcare sector averages

Net Margin
STME 0.0%
vs
Sector Avg 12.0%
STME Sector
ROE
STME 0.0%
vs
Sector Avg 15.0%
STME Sector
Current Ratio
STME 0.0x
vs
Sector Avg 2.0x
STME Sector
Debt/Equity
STME 0.0x
vs
Sector Avg 0.6x
STME Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Stimcell Energetics Inc. Stock Overvalued? STME Valuation Analysis 2026

Based on fundamental analysis, Stimcell Energetics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Stimcell Energetics Inc. Balance Sheet: STME Debt, Cash & Liquidity

Current Ratio
0.02x
Quick Ratio
0.02x
Debt/Equity
N/A
Debt/Assets
4,962.0%
Interest Coverage
N/A
Long-term Debt
N/A

STME Revenue & Earnings Growth: 5-Year Financial Trend

STME 5-year financial data: Year 2012: Revenue $0, Net Income N/A, EPS N/A. Year 2020: Revenue $95.8K, Net Income -$906.0K, EPS N/A. Year 2024: Revenue $2.8K, Net Income N/A, EPS $-0.01.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Stimcell Energetics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.

STME Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

STME Quarterly Earnings & Performance

Quarterly financial performance data for Stimcell Energetics Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2024 N/A -$17.5K $0.00
Q2 2021 $1.9K -$189.3K N/A
Q1 2021 $1.5K -$201.2K N/A
Q3 2020 N/A -$144.3K N/A
Q2 2020 N/A -$127.5K N/A
Q1 2020 N/A -$243.5K N/A
Q3 2015 $5.3K -$4.4K N/A
Q1 2013 N/A N/A N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Stimcell Energetics Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$268.6K
Cash generated from operations
Dividends
None
No dividend program

STME SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Stimcell Energetics Inc. (CIK: 0001493712)

📋 Recent SEC Filings

Date Form Document Action
Apr 10, 2026 10-Q stme-20260228_10q.htm View →
Mar 20, 2026 8-K stme-20260312_8k.htm View →
Jan 15, 2026 10-Q stme-20251130_10q.htm View →
Dec 19, 2025 4 xslF345X05/primary_doc.xml View →
Dec 2, 2025 8-K stme-20251202_8k.htm View →

Frequently Asked Questions about STME

What is the AI rating for STME?

Stimcell Energetics Inc. (STME) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are STME's key strengths?

Claude: Medical instruments sector could retain strategic value if company restructured or acquired. Minimal debt burden relative to equity deficit.

What are the risks of investing in STME?

Claude: Insolvency - liabilities ($1.7M) far exceed assets ($34.5K); negative equity of -$1.7M. Zero revenue and sustained operating losses of -$665.9K with no business generation.

What is STME's revenue and growth?

Stimcell Energetics Inc. reported revenue of $0.0.

Does STME pay dividends?

Stimcell Energetics Inc. does not currently pay dividends.

Where can I find STME SEC filings?

Official SEC filings for Stimcell Energetics Inc. (CIK: 0001493712) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is STME's EPS?

Stimcell Energetics Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is STME a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Stimcell Energetics Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is STME stock overvalued or undervalued?

Valuation metrics for STME: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy STME stock in 2026?

Our dual AI analysis gives Stimcell Energetics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is STME's free cash flow?

Stimcell Energetics Inc.'s operating cash flow is $-268.6K, with capital expenditures of $0.0.

How does STME compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.02 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 16, 2026 | Data as of: 2026-02-28 | Powered by Claude AI